Aiforia vs Visiopharm (2026)
Both are CE marked biomarker vendors with no FDA clearance and an A on AI centrality, so the split is breadth and assay independence versus regulatory volume and assay integration. If you want multi tumor suites that are not tied to one assay maker, plus a model building engine, start with Aiforia. If your laboratory runs Agilent assays and you want biomarker algorithms validated to them, start with Visiopharm. Aiforia spans five tumor types plus lymph node and offers Aiforia Create for building models. Visiopharm holds the deepest accumulation of IVDR clearances in this group, with the PD-L1 application marking its ninth, and sells its algorithms validated to Agilent assays and the Omnis platform, a benefit for Agilent shops and a constraint for everyone else.
- Not tied to an assay maker: the models run on whole slide images independent of any single assay vendor, unlike Visiopharm's APPs, which are validated to and sold alongside Agilent assays and the Omnis platform.
- A model building engine plus broad suites: Aiforia Create for developing custom models, alongside clinical coverage across five tumor types and lymph node.
- Vendor stability visibility from its Helsinki listing, which most private competitors here do not offer.
- The deepest IVDR clearance accumulation in this group: the PD-L1 application is its ninth IVDR clearance, a substantial certified portfolio under IVDR's stricter evidence bar.
- Assay validated integration for Agilent laboratories: the APPs are validated to Agilent assays and the Omnis platform and sold as the Visiopharm Diagnostic Package, giving a second procurement route.
- An unusually candid autonomy framing: its PD-L1 validation tested standalone algorithm analysis and algorithm assisted interpretation as distinct conditions, rather than reporting only the flattering pairing.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Aiforia and Visiopharm are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Aiforia | Visiopharm |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | 2013 | 2001 |
| Headquarters | Helsinki, Finland | Hoersholm, Denmark |
| Website | aiforia.com | visiopharm.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Aiforia its top capability grade on AI Centrality and Security Certifications and Trust Center. Set against Visiopharm, Aiforia grades higher on HIPAA and BAA Posture and Security Certifications and Trust Center. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
The AI Health Index awards Visiopharm its top capability grade on AI Centrality. Set against Aiforia, Visiopharm grades higher on AI Liability and Recourse, EHR and Interoperability Depth and Deployment Model and Data Residency. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
Questions buyers ask
Should we choose Aiforia or Visiopharm?
On the axes where the AI Health Index separates them, Aiforia grades higher on HIPAA and BAA Posture and Security Certifications and Trust Center, and Visiopharm grades higher on AI Liability and Recourse, EHR and Interoperability Depth and Deployment Model and Data Residency. Visiopharm leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Aiforia and Visiopharm differ most?
The widest separation the AI Health Index records between Aiforia and Visiopharm is on Security Certifications and Trust Center, where Aiforia grades A and Visiopharm grades C. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.
Where do Aiforia and Visiopharm grade the same?
The AI Health Index grades Aiforia and Visiopharm the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
Both are CE-IVD only with no FDA clearance, neither publishes pricing or a security attestation, and both report concordance and efficiency evidence rather than patient outcome. One portfolio caveat on Visiopharm a buyer should catch: its prostate APP is supplied by DeepBio and carries the older IVDD mark rather than IVDR, a lower evidence bar, so the certified portfolio is not uniform, and its validation is asserted across three sites without demographic subgroup analysis.
Aiforia's efficiency figures are vendor quoted and not independently verified, and its integration is asserted through partnerships rather than an enumerated connector list, which is why it grades lower on interoperability. Coverage in both cases depends on the specific tumor type, antibody clone, and assay in use at a given laboratory rather than on the vendor name.